Tenax Therapeutics (TENX) Equity Average (2016 - 2017)
Historic Equity Average for Tenax Therapeutics (TENX) over the last 5 years, with Q3 2017 value amounting to $10.7 million.
- Tenax Therapeutics' Equity Average fell 7803.99% to $10.7 million in Q3 2017 from the same period last year, while for Sep 2017 it was $10.7 million, marking a year-over-year decrease of 7803.99%. This contributed to the annual value of $43.8 million for FY2016, which is N/A changed from last year.
- Per Tenax Therapeutics' latest filing, its Equity Average stood at $10.7 million for Q3 2017, which was down 7803.99% from $12.7 million recorded in Q2 2017.
- Tenax Therapeutics' Equity Average's 5-year high stood at $48.8 million during Q3 2016, with a 5-year trough of -$1.7 million in Q2 2013.
- For the 3-year period, Tenax Therapeutics' Equity Average averaged around $16.7 million, with its median value being $12.7 million (2017).
- Over the last 5 years, Tenax Therapeutics' Equity Average had its largest YoY gain of 6392.16% in 2013, and its largest YoY loss of 17750.15% in 2013.
- Quarter analysis of 3 years shows Tenax Therapeutics' Equity Average stood at -$1.7 million in 2013, then soared by 1989.35% to $31.9 million in 2016, then plummeted by 66.43% to $10.7 million in 2017.
- Its last three reported values are $10.7 million in Q3 2017, $12.7 million for Q2 2017, and $15.6 million during Q1 2017.